The Pure Biologics’ CEO, Dr. Filip Jeleń, in Grzegorz Siemionczyk’s #PROSTOzPARKIET program talks about the goals of the third issue of shares, the progress of research projects and the expectations related to the transfer of the company from NewConnect to the main market of the Warsaw Stock Exchange.
Check video: 🎥 Pure Biologics: Trzecia emisja akcji będzie ostatnią (🇵🇱)